These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 15549216)

  • 1. [Pharmacological treatment in adults with attention deficit hyperactivity disorder].
    Frölich J; Lehmkuhl G
    Nervenarzt; 2004 Nov; 75(11):1074-82. PubMed ID: 15549216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological treatment of attention-deficit/hyperactivity disorder in adults].
    Rollini M; Baud P
    Rev Med Suisse; 2008 Jul; 4(165):1638-43. PubMed ID: 18767289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attention deficit/hyperactivity disorder across the lifespan.
    Wilens TE; Biederman J; Spencer TJ
    Annu Rev Med; 2002; 53():113-31. PubMed ID: 11818466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coming into focus. Pharmacologic treatment for ADHD.
    McDonnell MA; Moffett C
    Adv NPs PAs; 2010 Dec; 1(4):16-22; quiz 23. PubMed ID: 21319448
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pharmacotherapy of ADHD in adults with comorbid depression].
    Ohlmeier MD
    Psychiatr Prax; 2007 Sep; 34 Suppl 3():S296-9. PubMed ID: 17786887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability.
    Simonoff E; Taylor E; Baird G; Bernard S; Chadwick O; Liang H; Whitwell S; Riemer K; Sharma K; Sharma SP; Wood N; Kelly J; Golaszewski A; Kennedy J; Rodney L; West N; Walwyn R; Jichi F
    J Child Psychol Psychiatry; 2013 May; 54(5):527-35. PubMed ID: 22676856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attention deficit hyperactivity disorder and substance use disorders.
    Bukstein OG
    Curr Top Behav Neurosci; 2012; 9():145-72. PubMed ID: 21789746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Epilepsy and comorbid neurodevelopmental disorders].
    Nordin V; Olsson IB; Tomson T
    Lakartidningen; 2018 May; 115():. PubMed ID: 29786810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on adult attention-deficit/hyperactivity disorder.
    Hammerness P; Surman C; Miller K
    Curr Neurol Neurosci Rep; 2008 Nov; 8(6):484-9. PubMed ID: 18957185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylphenidate transdermal system.
    Mays DA; Findling R
    J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1223. PubMed ID: 16292112
    [No Abstract]   [Full Text] [Related]  

  • 12. Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder.
    Lakić A
    Vojnosanit Pregl; 2012 Feb; 69(2):201-4. PubMed ID: 22500377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
    Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder.
    Wilens TE; Biederman J; Prince J; Spencer TJ; Faraone SV; Warburton R; Schleifer D; Harding M; Linehan C; Geller D
    Am J Psychiatry; 1996 Sep; 153(9):1147-53. PubMed ID: 8780417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sleep characteristics of children and adolescents with attention deficit-hyperactivity disorder.
    Gruber R
    Child Adolesc Psychiatr Clin N Am; 2009 Oct; 18(4):863-76. PubMed ID: 19836693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does collateral retrospective information about childhood attention-deficit/hyperactivity disorder symptoms assist in the diagnosis of attention-deficit/hyperactivity disorder in adults? Findings from a large clinical sample.
    Breda V; Rovaris DL; Vitola ES; Mota NR; Blaya-Rocha P; Salgado CA; Victor MM; Picon FA; Karam RG; Silva KL; Rohde LA; Bau CH; Grevet EH
    Aust N Z J Psychiatry; 2016 Jun; 50(6):557-65. PubMed ID: 26460329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How high a dose of stimulant medication in adult attention deficit hyperactivity disorder?
    Sachdev PS; Trollor JN
    Aust N Z J Psychiatry; 2000 Aug; 34(4):645-50. PubMed ID: 10954396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Childress AC
    Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adult attention deficit/hyperactivity disorder].
    Laufkötter R; Eichhammer P; Hajak G
    MMW Fortschr Med; 2004 Aug; 146(33-34):31-4. PubMed ID: 15526623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.